KR20180042916A - Beverage composition having an outstanding absorptive property of collagen peptide - Google Patents
Beverage composition having an outstanding absorptive property of collagen peptide Download PDFInfo
- Publication number
- KR20180042916A KR20180042916A KR1020160135485A KR20160135485A KR20180042916A KR 20180042916 A KR20180042916 A KR 20180042916A KR 1020160135485 A KR1020160135485 A KR 1020160135485A KR 20160135485 A KR20160135485 A KR 20160135485A KR 20180042916 A KR20180042916 A KR 20180042916A
- Authority
- KR
- South Korea
- Prior art keywords
- collagen peptide
- collagen
- beverage composition
- extract
- blood
- Prior art date
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 68
- 108010035532 Collagen Proteins 0.000 title claims abstract description 68
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 67
- 229920001436 collagen Polymers 0.000 title claims abstract description 66
- 235000013361 beverage Nutrition 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 26
- 239000008280 blood Substances 0.000 claims abstract description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 230000001766 physiological effect Effects 0.000 abstract description 2
- 241001106041 Lycium Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229960002591 hydroxyproline Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000037394 skin elasticity Effects 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KSUIAQLWKGDNGR-BZLSRIERSA-N (2S)-2-amino-3-phenylpropanoic acid (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound O[C@H]1CN[C@H](C(O)=O)C1.OC(=O)[C@@H](N)CC1=CC=CC=C1 KSUIAQLWKGDNGR-BZLSRIERSA-N 0.000 description 2
- SPJNOEYGWJSUCD-DNEVJOFISA-N (2s,3s)-2-amino-3-methylpentanoic acid;(2s,4r)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(O)=O.O[C@H]1CN[C@H](C(O)=O)C1 SPJNOEYGWJSUCD-DNEVJOFISA-N 0.000 description 2
- OOGFPFWTORZYAN-AQHGXSAQSA-N (2s,4r)-4-oxidanylpyrrolidine-2-carboxylic acid Chemical compound O[C@H]1CN[C@H](C(O)=O)C1.O[C@H]1CN[C@H](C(O)=O)C1 OOGFPFWTORZYAN-AQHGXSAQSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940117953 phenylisothiocyanate Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- QEDRTIXTEAXNMY-XVMARJQXSA-N 2-[[(2s,4r)-1-[(2s)-2-aminopropanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetic acid Chemical compound C[C@H](N)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(O)=O QEDRTIXTEAXNMY-XVMARJQXSA-N 0.000 description 1
- FVSSRXSXSBLAOD-UHFFFAOYSA-N 6-hydroxy-2-phenyl-3-sulfanylidene-5,6,7,7a-tetrahydropyrrolo[1,2-c]imidazol-1-one Chemical compound C1C(O)CC(C2=O)N1C(=S)N2C1=CC=CC=C1 FVSSRXSXSBLAOD-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WJSNJMXOBDSZDL-WOPDTQHZSA-N L-phenylalanyl-L-hydroxyproline Chemical compound C([C@H](N)C(=O)N1[C@@H](C[C@@H](O)C1)C(O)=O)C1=CC=CC=C1 WJSNJMXOBDSZDL-WOPDTQHZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000201976 Polycarpon Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000020687 goji berry extract Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- -1 zeazanthin Natural products 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 콜라겐 펩타이드 음료 조성물에 관한 것으로서, 더욱 상세하게는 콜라겐 펩타이드의 혈중 이행성이 우수한 음료 조성물에 관한 것이다.TECHNICAL FIELD The present invention relates to a collagen peptide beverage composition, and more particularly to a beverage composition having an excellent blood transitivity of a collagen peptide.
콜라겐은 진피, 인대, 힘줄, 뼈, 연골 등을 구성하는 단백질의 하나로, 다세포 동물의 세포 외 기질(세포 외 매트릭스)의 주성분이다. 콜라겐은 피부, 혈관, 내장, 뼈 조직 등 여러 곳에 존재하고, 몸을 구성하는 단백질의 약 30%를 차지하며. 피부에서는 진피의 70%가 콜라겐으로 되어 있고, 개개 근육을 둘러싸는 근막도 콜라겐으로 되어 있다.Collagen is one of the proteins that make dendrites, ligaments, tendons, bones, cartilage, etc., and it is the main component of extracellular matrix (extracellular matrix) of multicellular animal. Collagen is present in many places such as skin, blood vessels, internal organs and bone tissue, and it accounts for about 30% of the proteins that make up the body. In the skin, 70% of the dermis is made of collagen, and the fascia surrounding individual muscles is made of collagen.
콜라겐 단백질은 Gly-X-Y(X, Y는 Gly 이외의 아미노산)라는 반복 구조를 갖는 분자량 약 10만의 폴리펩타이드쇄(α쇄)가 3개 모여 나선 구조를 취하고 있다.The collagen protein has a spiral structure in which three polypeptide chains (? Chains) having a molecular weight of about 100,000 having a repeating structure of Gly-X-Y (X and Y are amino acids other than Gly)
콜라겐 단백질은 히드록시프롤린이나 히드록시리신 등 콜라겐 특유의 아미노산을 갖는 반면, 필수 아미노산인 트립토판을 갖지 않기 때문에, 아미노산 스코어가 제로이고, 영양소로서는 역사적으로 주목받지 못하였다.The collagen protein has collagen-specific amino acids such as hydroxyproline and hydroxylysine, while it does not have the essential amino acid tryptophan. Therefore, the amino acid score is zero, and it has not attracted historical attention as a nutrient.
그러나 최근 콜라겐의 수많은 생리 작용이나 약리 작용이 발견되고, 콜라겐, 콜라겐을 가열 변성시킨 젤라틴 및 이들의 가수 분해물인 콜라겐 펩타이드는 화장품 및 식품용 원재료나 의약품용 생체 기능성 재료로서 폭넓게 이용되고 있다. Recently, however, many physiological actions and pharmacological actions of collagen have been found, and collagen and collagen, which are heat-denatured gelatin, and collagen peptide, which is a hydrolyzate thereof, have been widely used as raw materials for cosmetics and foods and as biofunctional materials for pharmaceuticals.
지금까지 콜라겐의 생리 작용이나 약리 작용으로서, 골다공증의 예방ㆍ개선에 결부되는 골아 세포 증식 촉진 작용, 뼈 강화 작용, 노화에 따른 생체 조직 기능의 저하를 개선하는 생체 조직의 신진 대사 촉진 작용, 피부 대사 촉진 작용, 피부 부활 작용 등이 밝혀지고 있다. 그러나, 이와 같은 종래 기술에서와 같은 생리 작용이나 약리 작용을 충분히 발휘시키기 위해서는 콜라겐 펩타이드를 다량 섭취할 필요가 있었다.As a physiological or pharmacological action of collagen, there has been known a method for promoting osteoporosis by promoting osteoporosis, promoting osteoporosis, bone strengthening action, metabolism promoting action of biotissue to improve deterioration of biotissue function due to aging, Accelerating action, and skin resurrection. However, in order to sufficiently exhibit the physiological action and pharmacological action as in the conventional art as described above, it has been necessary to take a large amount of the collagen peptide.
또한, 다니구찌 등은 콜라게나제 처리에 의한 콜라겐 펩타이드와 동일 비율의 아미노산 혼합물에 대하여 각각 래트에 있어서의 피부 콜라겐의 합성 촉진 효과를 비교 검토한 결과, 아미노산 혼합물에서는 효과가 보이지 않고, 콜라게나제에 의한 콜라겐 펩타이드에서만 효과가 보인 것을 보고하였다(비 특허 문헌 1). In addition, Taniguchi et al. Each examined the effect of promoting the synthesis of skin collagen in rats against a mixture of amino acids at the same ratio as collagen peptide by collagenase treatment. As a result, no effect was observed in the amino acid mixture, (See Non-Patent Document 1).
따라서, 이 결과는, 콜라겐 펩타이드의 생리 작용이나 약리 작용은 아미노산으로서 체 내에 흡수되어 단백질이 재구성됨으로써 발휘되는 것은 아니고, 혈중으로 이행된 콜라겐 펩타이드에 의해서 발휘됨을 시사한다.Therefore, this result suggests that the physiological or pharmacological action of the collagen peptide is not exerted by absorption of the amino acid into the body and reconstitution of the protein, but by the collagen peptide transferred into the blood.
그러나 경구 섭취된 경우의 콜라겐 펩타이드의 혈중 이행성을 개선하는 특허는 전혀 나타나고 있지 않다.However, no patent has been developed to improve the blood circulation of collagen peptides when taken orally.
따라서 본 발명이 해결하고자 하는 과제는 콜라겐 펩타이드의 혈중 이행성을 개선시킨 콜라겐 펩타이드 음료를 제공하는 것이다.Accordingly, a problem to be solved by the present invention is to provide a collagen peptide beverage which improves blood circulation of collagen peptide.
상기 기술적 과제를 달성하기 위하여, 본 발명은According to an aspect of the present invention,
콜라겐 펩타이드 및 구기자 추출물을 포함하는 것을 특징으로 콜라겐 펩타이드 혈중 이행성 향상 음료 조성물을 제공한다.A collagen peptide, and a gum extract, to provide a beverage composition for improving collagen peptide blood transitability.
본 발명에 따른 음료 조성물에 있어서, 상기 구기자 추출물은 구기자 발효 추출물일 수 있다.In the beverage composition according to the present invention, the gugija extract may be a gugija fermentation extract.
본 발명에 따른 음료 조성물에 있어서, 상기 구기자 추출물의 추출 용매가 물 또는 에탄올인 것이 바람직하다.In the beverage composition according to the present invention, it is preferable that the extract solvent of the Gujuga extract is water or ethanol.
본 발명에 따른 음료 조성물에 있어서, 상기 구기자 추출물은 콜라겐 펩타이드 100중량 대비 0.5 내지 50중량부인 것이 바람직하다.In the beverage composition according to the present invention, it is preferable that the gugija extract is 0.5 to 50 parts by weight per 100 parts by weight of the collagen peptide.
본 발명에 따른 콜라겐 펩타이드 음료는 콜라겐 펩타이드 혈중 이행성이 우수하여 콜라겐 펩타이드의 피부 미용 등의 다양한 생리 활성을 더욱 효과적으로 이용할 수 있는 장점이 있다. The collagen peptide beverage according to the present invention has an advantage of being able to more effectively utilize various physiological activities such as skin beauty of collagen peptide because of its excellent blood circulation of collagen peptide.
이하 본 발명을 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in detail.
본 발명은 콜라겐 펩타이드의 혈중 이행성을 높이기 위하여 구기자 추출물을 더 포함시킨 콜라겐 펩타이드 음료를 제공한다.The present invention provides a collagen peptide beverage further comprising a Gugija extract for enhancing blood transitivity of the collagen peptide.
본 발명에서 사용되는 콜라겐 펩타이드는 포유류, 조류, 어류 등 그 유래 및 분자량 등에 제한을 받지 않고 음료 분야에 사용되는 콜라겐 펩타이드라면 아무 조건없이 사용가능하며, 흡수율이 높은 것으로 알려진 저 분자량의 펩타이드, 나노 펩타이드를 사용하게 되면 혈중 이행성이 높아지는 것은 당연하며, 본 발명에서는 동일한 콜라겐 펩타이드일지라도 구기자 추출물과 함께 음료로 섭취하게 되면 콜라겐 펩타이드의 혈중 이행성이 향상되는 것으로, 콜라겐 펩타이드의 종류의 변화에서 오는 효과가 아닌 구기자 추출물과 함께 섭취함으로써 발휘되는 효과이다.The collagen peptide used in the present invention can be used without any restriction if it is a collagen peptide used in the beverage field without being limited to the origin and molecular weight of mammals, algae, fish, etc. Low molecular weight peptide, nanopeptide It is natural that the blood transitivity is increased. In the present invention, even if the same collagen peptide is ingested as a beverage with the extract of Gugija, the blood transitivity of the collagen peptide is improved, and the effect of the change in the type of collagen peptide It is an effect to be exerted by ingesting with a non-ginger extract.
본 발명의 음료 조성물 중 유효 성분으로 사용되는 구기자(GLycii fructus)는 가지과에 속하는 구기자 나무의 열매로서 열매는 원형 또는 타원형의 장과(漿果:살과 물이 많고 씨앗이 있는 열매)이고, 8·9월에 붉게 익는다. 길이는 10㎜, 지름은 5㎜정도이다. 처음에는 달콤하나 나중에는 쓴맛을 낸다. 건조시켰을 때에 겉이쭈글쭈글하고, 속에는 많은 씨가 들어 있다. 씨는 편평하고 콩팥 모양이며, 지름이 약 2㎜ 정도이고 황백색이다. 열매의 모양과 색깔이 예쁘고 작아서 고서에는 ‘괴좃나무여름’이라고도 하였다. 현재 우리 나라에서는 충청남도 청양군이 집산지이다.GLycii fructus, which is used as an active ingredient in the beverage composition of the present invention, is a fruit of Gugija which belongs to the genus Ganoderma. The fruit is a round or elliptical fruit (fruit with many flesh and water and seeds) It rips red in September. The length is 10 mm and the diameter is about 5 mm. It is sweet at first and bitter afterwards. When it is dry, it crumble on the outside, and there are many seeds inside. The seeds are flat, kidney-shaped, about 2mm in diameter and yellowish white. Because the shape and color of the fruit is pretty and small, it is said to be the "좃좃 木 夏" in ancient times. Currently, Cheongyang County in Chungcheongnam-do is the distributing center in our country.
성분은 베타인(betaine)·제아잔틴(zeazanthin)·카로틴(carotene)·티아민(thiamine), 비타민 A·B1·B2·C등이 함유되어 있다. 동물실험을 한 결과, 베타인 성분은 생체 내 대사물질의 하나인 친지질물질(親脂質物質:지방에 가까운 물질)로 밝혀졌다. 간장에서 지방의 축적을 억제하고 간세포의 신생을 촉진하며, 혈압을 내려주는 작용도 한다. 약성(藥性)은 평범하고 독이 없다. 효능은 만성간염·간경변증 등에 복용하면 염증이 제거되고 기능을 활성화시킨다. 일반적으로 생식기능이 허약해서 허리·무릎이 저리고 아프고, 유정(遺精)·대하(帶下) 등의 증상에 유효하다. 안과질환으로 인한 시력감퇴 등에 효과가 있고, 노인의 백내장 초기증상에 응용한다.Ingredients include betaine, zeazanthin, carotene, thiamine, and vitamins A, B1, B2, and C. As a result of animal experiments, beta-phosphorus was found to be a lipid substance (lipid substance: fat-like substance), which is one of the metabolites in vivo. It inhibits the accumulation of fat in the liver, promotes hepatocyte development, and lowers blood pressure. Medicinal (medicinal) is mediocre and not poisonous. Efficacy of chronic hepatitis, liver cirrhosis, etc., when the inflammation is removed and the function is activated. Generally, the reproductive function is weak, and the back and the knee are sore, and it is effective for the symptoms such as the oiliness, the fatigue, and the fever. It is effective for the reduction of visual acuity due to ophthalmologic diseases and it is applied to the early symptoms of cataract in the elderly.
본 발명에 있어서, 구기자 추출물은 콜라겐 펩타이드의 혈중 이행을 높이는 성분으로 사용이 된다.In the present invention, Gugija extract is used as a component for enhancing blood transfusion of collagen peptide.
본 발명에서 이용 가능한 구기자 추출물은 통상적인 온도와 압력의 조건 하에서, 통상적인 용매를 사용하여 제조될 수 있으며, 바람직하게는 (a) 물, 탄소수 1 ~ 4의 무수 또는 함수 저급 알코올(예를 들면, 메탄올, 에탄올, 프로판올 및 부탄올), 프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 아세톤, 디에틸에테르, 에틸 아세테이트, 부틸아세테이트, 디클로로메탄, 클로로포름, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 용매를 이용한 용매 추출법, (b)이산화탄소에 의한 감압 및 고온에 의한 초임계 추출법, 또는 (c) 초음파 추출법을 이용하여 추출하여 제조될 수 있다.The gojiwa extracts usable in the present invention can be prepared using conventional solvents under the conditions of ordinary temperature and pressure, and preferably include (a) water, an anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms Selected from the group consisting of methanol, ethanol, propanol and butanol), propylene glycol, 1,3-butylene glycol, glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane and mixtures thereof (B) decompression by carbon dioxide and supercritical extraction at a high temperature, or (c) extraction using an ultrasonic extraction method.
또한 본 발명의 구기자 추출물에는 구기자 발효 추출물이 포함되며, 본 발명이 속하는 기술 분야 널리 알려진 구기자 발효 추출물이라면 특별한 제한 없이 이용가능하며, 발효 균주의 예로는 효모, 버섯균사체, 유산균류 등을 들 수 있다.The gugija extract of the present invention includes a gugija fermentation extract and can be used without any particular limitation if it is a well-known gugija fermentation extract in the art to which the present invention belongs. Examples of the fermentation strain include yeast, mushroom mycelium, .
본 발명에 있어서, 구기자 추출물과 콜라겐 펩타이드의 함량 비율은 특별한 제한을 받지 않으나 구기자 추출물이 콜라겐 펩타이드 100중량 대비 0.5 내지 50중량부인 것이 바람직하다.In the present invention, the ratio of the extract of Gujuga extract to the content of collagen peptide is not particularly limited, but it is preferable that the Gujuga extract is 0.5 to 50 parts by weight based on 100 parts by weight of the collagen peptide.
또한 본 발명에 따른 음료 조성물은 감미료, 보존제, 다른 다양한 활성 성분을 포함할 수 있으며, 이는 본 발명이 속하는 기술 분야에 널리 알려져 있는 것이라면 특별한 제한 없이 사용할 수 있으며, 그 예로는 구연산, 비오틴, 천연 토코페롤, 나이아신 아마이드 등을 들 수 있다.In addition, the beverage composition according to the present invention may contain a sweetener, a preservative, and various other active ingredients, and is not particularly limited as long as it is well known in the art to which the present invention belongs. Examples thereof include citric acid, biotin, natural tocopherol , Niacinamide, and the like.
이하 본 발명을 실시예 및 시험예를 통하여 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in detail with reference to Examples and Test Examples.
(( 실시예Example 1) 본 발명의 콜라겐 1) The collagen of the present invention 펩타이드Peptides 음료 조성물의 제조 Preparation of beverage composition
세척하여 건조한 구기자 100g을 3ℓ플라스크에 넣고 정제수 2,000㎖을 이용하여 100℃에서 환류 교반시키면서 8시간 동안 가열추출을 3회 반복 실시하였다. 상기 추출액을 모아 여과한 후, 40℃ 이하에서 회전식 진공농축증발기를 사용하여 진공 감압 농축시켜 500ml로 농축하였고 원심분리(3,000 rpm, 20분) 후 상층액 만을 모아 이를 다시 동결건조시켜 분말한 다음 이 분말 100mg에 분자량 400달톤의 생선 비늘 유래 콜라겐 펩타이드 2500mg와 혼합한 다음에 이를 정제수 100ml에 녹여 본 발명에 따른 음료를 제조하였다.100 g of dried gugija was placed in a 3-liter flask, and heated and extracted for 3 hours with 2,000 ml of purified water at 100 ° C while stirring under reflux. The extracts were collected and concentrated by filtration and concentrated under reduced pressure using a rotary vacuum evaporator at 40 ° C or lower. After concentration by centrifugation (3,000 rpm, 20 minutes), the supernatant was collected, 100 mg of the powder was mixed with 2500 mg of a fish scale-derived collagen peptide having a molecular weight of 400 daltons and then dissolved in 100 ml of purified water to prepare a beverage according to the present invention.
(( 비교예Comparative Example 1) 종래의 콜라겐 1) Conventional collagen 펩타이드Peptides 음료 조성물의 제조 Preparation of beverage composition
실시예 1에서 구기자 추출물을 아세로라 추출물 분말로 변경한 것을 제외하고는 동일한 방법으로 콜라겐 펩타이드 음료 조성물을 제조하였다.A collagen peptide beverage composition was prepared in the same manner as in Example 1 except that the extract of Aspergillus species was changed to the powder of Asperiae extract.
(( 비교예Comparative Example 2) 종래의 콜라겐 2) Conventional collagen 펩타이드Peptides 음료 조성물의 제조 Preparation of beverage composition
실시예 1에서 구기자 추출물을 사용하지 않은 것을 제외하고는 동일한 방법으로 콜라겐 펩타이드 음료 조성물을 제조하였다.A collagen peptide beverage composition was prepared in the same manner as in Example 1, except that no goji extract was used.
(( 시험예Test Example 1) 혈중으로의 1) 이행성Transitionality 비교 시험(흡수성 시험) Comparative Test (Absorbency Test)
시험은 이와이 등의 보고(문헌[Agric. Food Chem., 2005, Vol.53, No.16, p6531-[0075] 6536])에 기초하여 행하였다.The test was conducted based on the report of Iwai et al. (Agric. Food Chem., 2005, Vol. 53, No. 16, p6531- [0075] 6536).
자원 봉사자 5명에 대하여 6 일간 이상의 워시 아웃(wash out) 기간을 두고, 피험자 1인에 대하여 상기 실시예 및 비교예의 콜라겐 펩타이드 음료 조성물의 전체 종류를 피검 시료로 하여, 각각 1회 섭취시키는 크로스오버 시험으로 하였다.Five volunteers were subjected to a washout period of 6 days or more, and one subject was subjected to a crossover in which all kinds of the collagen peptide beverage composition of the above Examples and Comparative Examples were used as test samples, Test.
피험자는 12 시간의 절식 후, 섭취 전 채혈을 행하고, 각 피검 시료를 섭취하였다. 피검 시료의 섭취량은 25g/체중 65kg으로 하였다. 섭취 0.5, 1, 2, 4, 7 시간 후에 각각 5 mL 채혈하였으며, 약 15 분간 얼음 중에서 방치시킨 후, 원심 분리(3000 rpm, 15 분, 4 ℃)를 행하여 혈장을 얻었다.After the fasting for 12 hours, the subject was pre-ingested and each test sample was taken. The amount of the sample to be tested was 25 g / body weight 65 kg. 5 mL of blood was collected at 0.5, 1, 2, 4, and 7 hours after the ingestion, and left in ice for about 15 minutes and centrifuged (3000 rpm, 15 minutes, 4 ° C) to obtain plasma.
혈장 300 μL에 에탄올 900 μL를 첨가하여 볼텍스로 15 초간 교반하고, 원심 분리(12,000 rpm, 10 분, 4 ℃)하여 상청을 얻었다. 각 피험자, 각 채혈 시간의 혈장을 분석할 때까지 -80 ℃에서 동결 보존하였다.900 μL of ethanol was added to 300 μL of plasma, stirred for 15 seconds with a vortex, and centrifuged (12,000 rpm, 10 minutes, 4 ° C.) to obtain supernatant. Each subject was cryopreserved at -80 ° C until analysis of plasma at each sampling time.
혈장 중의 펩타이드형 히드록시프롤린량은, 총 히드록시프롤린(히드록시프롤린)량과 유리형 히드록시프롤린량을 각각 측정하고, 그 차로부터 구하였다. 총 히드록시프롤린(히드록시프롤린)은 사또 등(문헌[Sato K. et al., J. Agric. Food Chem. 1992, 40, 806-810])의 방법에 준하여 혈장 샘플을 6 N 염산을 이용해 가수분해 후, 페닐이소티오시아네이트(PITC) 유도하고, 하기 조건에서 HPLC를 행하여 측정하였다. 또한, 혈장 중의 유리형 히드록시프롤린량은 단백 제거한 혈장 샘플에 대하여 동일한 조건에서 HPLC를 행하여 측정하였다.The amount of peptide-type hydroxyproline in the plasma was determined by measuring the total amount of hydroxyproline (hydroxyproline) and the amount of free hydroxyproline, respectively. Total hydroxyproline (hydroxyproline) was measured by the method of Sato K. et al., J. Agric. Food Chem., 1992, 40, 806-810) using 6 N hydrochloric acid After hydrolysis, phenyl isothiocyanate (PITC) was induced and subjected to HPLC under the following conditions. In addition, the amount of free hydroxyproline in the plasma was measured by performing HPLC under the same conditions on the plasma sample from which the protein was removed.
(분석 조건)(Analysis condition)
컬럼: TSK80TsQA(250×2.0 mm)Column: TSK80TsQA (250 x 2.0 mm)
용리액: (A액) 50 mM 아세트산나트륨 완충액(pH 6)Eluent: (A solution) 50 mM sodium acetate buffer (pH 6)
(B액) 아세토니트릴(Solution B) Acetonitrile
용출 조건: B액 5 내지 10 %(0 내지 8 분), B액 70 %(8 내지 11 분), B액 5 %(11 분)Elution conditions: 5 to 10% (0 to 8 minutes) of solution B, 70% (8 to 11 minutes) of solution B, 5% (11 minutes)
유속: 0.18 mL/분Flow rate: 0.18 mL / min
검출 파장: 254 nmDetection wavelength: 254 nm
각 혈장 샘플에 대하여 산출된 펩타이드형 히드록시프롤린의 혈중 농도-시간 곡선하 면적 AUC0-7양(hrㆍnmol/ml)의 평균값±S.E.를 하기 표 1에 나타내었다.The average value of the amount of AUC0-7 (hr · nmol / ml) ± S.E. Under the blood concentration-time curve of the peptide-type hydroxyproline calculated for each plasma sample is shown in Table 1 below.
(hr·nmol/ml: 평균값 ± SE)Amount of peptide-type hydroxyproline
(hr · nmol / ml: mean value ± SE)
또한, 혈중의 펩타이드형 히드록시프롤린량은 섭취 후 1 내지 2 시간에 피크를 나타내었다. 표 2에는 각 콜라겐 펩타이드를 섭취하고 1 시간 후 및 2 시간 후의 펩타이드형 히드록시프롤린량(nmol/ml)의 평균값±S.E.를 나타내었다.In addition, the amount of peptide-type hydroxyproline in the blood showed a peak at 1 to 2 hours after ingestion. Table 2 shows the average values of peptide-type hydroxyproline (nmol / ml) ± SEE. After 1 hour and 2 hours after each collagen peptide was ingested.
상기 표 1에 나타난 바와 같이, AUC를 비교하면 본 발명의 콜라겐 펩타이드 음료 조성물의 혈중 이행성은 다른 비교예의 콜라겐 펩타이드 음료 조성물의 그것보다 유의하게 증대하였다. As shown in Table 1, when comparing the AUC, the blood transitivity of the collagen peptide beverage composition of the present invention was significantly increased compared to that of the collagen peptide beverage composition of the other comparative examples.
또한, 표 2에 나타낸 바와 같이, 본 발명의 콜라겐 펩타이드 음료 조성물을 섭취하고 1 시간 후 및 2 시간 후의 혈중 이행성은 종래의 콜라겐 펩타이드 음료 조성물과 비교하여 현저하게 증대하였다.In addition, as shown in Table 2, the blood transitivity after 1 hour and 2 hours after ingestion of the collagen peptide beverage composition of the present invention was remarkably increased as compared with the conventional collagen peptide beverage composition.
( 시험예 2) 콜라겐 펩타이드 조성물 경구 섭취 후의 혈중의 펩타이드 조성 (Test Example 2) The collagen peptide composition of the peptide after oral intake the blood composition
시험예 1에서 채취한 혈장 샘플의 에탄올 상청 분획을 원심진공 건조기로 건고(乾固) 후, 0.1 % 트리플루오로아세트산을 포함하는 30 % 아세토니트릴 200 μL를 첨가하여 용해시키고, 하기 조건에서 HPLC로 분획하였다.The ethanol supernatant fraction of the plasma sample collected in Test Example 1 was dried (dried) in a centrifugal vacuum drier, and then 200 μL of 30% acetonitrile containing 0.1% trifluoroacetic acid was added and dissolved. Lt; / RTI >
(분석 조건)(Analysis condition)
칼럼: 수퍼덱스 펩타이드 HR10/30(아머샴 파마시아(Amersham Pharmacia), 미국 뉴저지주 피스카타웨이)Column: Superdext Peptide HR10 / 30 (Amersham Pharmacia, Piscataway, NJ)
용리액: 30 % 아세토니트릴(0.1 % 트리플루오로아세트산 함유)Eluent: 30% acetonitrile (containing 0.1% trifluoroacetic acid)
유속: 0.5 mL/분Flow rate: 0.5 mL / min
검출 파장: 230 nmDetection wavelength: 230 nm
칼럼 온도: 실온Column temperature: room temperature
분석 시간: 60 분Analysis time: 60 minutes
용출 샘플은 분획 수집기로 1 분마다 회수하였다. 겔 여과 크로마토그래피로 얻은 분자량 200 내지 500의 분획을 펩타이드 분획으로서 원심 진공 건조기로 약 50 μL로 농축시키고, 하기 조건에서 역상 크로마토그래피로 분획하였다.The eluted sample was collected every minute with a fraction collector. Fractions of 200-500 molecular weight obtained by gel filtration chromatography were concentrated as a peptide fraction to about 50 L using a centrifugal vacuum drier and fractionated by reverse phase chromatography under the following conditions.
(분석 조건)(Analysis condition)
칼럼: 이너트실(Inertsil) ODS-3(250 mm×4.6 mm i.d., GL 사이언스(GL Science), 도쿄)Column: Inertsil ODS-3 (250 mm x 4.6 mm i.d., GL Science, Tokyo)
용리액: (A액) 0.1 % 트리플루오로아세트산Eluent: (liquid A) 0.1% trifluoroacetic acid
(B액) 80 % 아세토니트릴(0.1 % 트리플루오로아세트산 함유)(Liquid B) 80% acetonitrile (containing 0.1% trifluoroacetic acid)
용출 조건: B액 0 %(0 내지 15 분), B액 0 내지 50 %(15 내지 30 분), B액 100 %(30 내지 40 분), B 액 0%(40 내지 55 분)Elution condition: B solution 0% (0-15 minutes), B solution 0-50% (15-30 minutes), B solution 100% (30-40 minutes), B solution 0% (40-55 minutes)
유속: 1 mL/분Flow rate: 1 mL / min
칼럼 온도: 43.0 ℃Column temperature: 43.0 DEG C
검출 파장: 230 nmDetection wavelength: 230 nm
역상 크로마토그래피로 분획된 각 피크에 대하여 아미노산 분석과 프로틴 시퀀스를 행하고, 각 콜라겐 펩타이드 조성물 경구 섭취 후의 혈중의 펩타이드 조성을 산출하였다. 아미노산 분석은 사또 등(문헌[Sato K. et al., J. Agric. Food Chem. 1992, 40, 806-810])의 방법에 준하여 시험예 1과 동일하게 분석하였다. 단, 표준물로서 PTH 아미노산 표준 혼합액(어플라이드 바이오시스템사 제조) 및 PTH 히드록시프롤린 제조액(어플라이드 바이오시스템사 제조)을 이용하였다. 프로틴 시퀀서는 각 피크의 분획액을 PVDF(폴리불화비닐리덴)막에 적하 후, 프로틴 시퀀서(어플라이드 바이오시스템)를 이용하여 분석하였다. 대표적인 결과인 섭취 1 시간 후의 데이터를 하기 표 3에 나타내었다.Amino acid analysis and protein sequencing were performed on each of the peaks fractionated by reverse phase chromatography to calculate the peptide composition in blood after oral ingestion of each collagen peptide composition. Amino acid analysis was carried out in the same manner as in Test Example 1 according to the method of Sato et al. (Sato K. et al., J. Agric. Food Chem. 1992, 40, 806-810). As standard, PTH amino acid standard mixture (manufactured by Applied Biosystems) and PTH hydroxyproline (manufactured by Applied Biosystems) were used. The protein sequencer was dripped on each PVDF (polyvinylidene) membrane and analyzed using a Protein Sequencer (Applied Biosystems). Representative results, data after 1 hour of ingestion, are shown in Table 3 below.
상기 표 3에 나타낸 바와 같이, 종래의 음료를 섭취한 경우 펩타이드 조성의 대부분은 프롤린-히드록시프롤린의 이량체이고, 이소류신-히드록시프롤린, 류신-히드록시프롤린, 페닐알라닌-히드록시프롤린 등의 이량체도 보였다. 이에 대하여, 본 발명의 콜라겐 펩타이드 음료 조성물을 경구 섭취한 후의 혈중의 펩타이드 조성은 종래의 프롤린-히드록시프롤린, 이소류신-히드록시프롤린, 류신-히드록시프롤린, 페닐알라닌-히드록시프롤린 등의 이량체뿐 아니라 알라닌-히드록시프롤린-글리신, 세린-히드록시프롤린-글리신 등의 삼량체도 존재하였다.As shown in Table 3, when the conventional beverage was consumed, most of the peptide composition was a dimer of proline-hydroxyproline, and the amount of isoleucine-hydroxyproline, leucine-hydroxyproline and phenylalanine-hydroxyproline The body looked. On the other hand, the composition of peptides in the blood after orally ingesting the collagen peptide beverage composition of the present invention is lower than that of conventional peptides such as proline-hydroxyproline, isoleucine-hydroxyproline, leucine-hydroxyproline and phenylalanine-hydroxyproline But also trimers such as alanine-hydroxyproline-glycine, serine-hydroxyproline-glycine and the like.
따라서, 본 발명의 콜라겐 펩타이드 음료 조성물을 경구 섭취하면, 종래 혈중으로 이행되지 않은 펩타이드체도 새롭게 이행되는 것을 확인할 수 있었다. Therefore, when the collagen peptide beverage composition of the present invention is orally ingested, it has been confirmed that a peptide body which has not been transfused into blood has been newly transplanted.
(( 시험예Test Example 3) 피부 보습 및 탄력 효과 3) Skin moisturizing and elastic effect
실시예 및 비교예 음료에 대하여 피부 보습 및 탄력 효과에 대한 임상시험을 실시하였다. EXAMPLES AND COMPARATIVE EXAMPLES [0042] Clinical trials were conducted on skin moisturizing and elasticity effects on beverages.
피부탄력성에 대한 식물성 스테롤의 영향을 실험하기 위해 피검자 20명의 하루 한 번 음료 100㎖를 복용하였다. 음료를 복용하기 전과 복용하고 난 20일 후 피부 표면의 피부 탄력성을 피부수분측정기 CM 80과 피부탄력측정기 SEM 474에 의해 측정하였다. 피부수분측정기 CM 820에 의한 피부 보습 측정은 복용 전에 비해 증가한 보습력 값을 %로 나타내었으며, 피검자 20명의 평균값을 결과에 나타내었다. 피부탄력측정기 SEM 474에 의한 피부 탄력도 측정은 주름의 깊이를 측정하는 것으로서, 값이 적을수록 탄력성이 좋은 것이다. 탄력도 값은 복용 전에 비해 감소한 값을 %로 나타내었으며, 피검자 20명의 평균값을 결과에 나타내었다.To test the effect of plant sterols on skin elasticity, one hundred twenty drinkers were taken once daily for 20 subjects. Skin elasticity of the skin surface before and 20 days after taking the drink was measured by skin moisture meter CM 80 and skin elasticity meter SEM 474. The skin moisturizing measurement by CM 820 of skin moisture meter showed an increase in moisture value in% compared with before taking, and the average value of 20 subjects was shown in the result. The skin elasticity measurement by the skin elasticity measuring device SEM 474 measures the depth of the wrinkle, and the smaller the value, the better the elasticity. The elasticity value was expressed as a percentage of the decrease compared to before use, and the average value of 20 subjects was shown in the result.
상기 표 4로부터 알 수 있는 바와 같이, 본 발명의 음료가 피부 보습 및 탄력도 개선 효과가 비교예의 음료보다 현저하게 우수함을 알 수 있었다.As can be seen from the above Table 4, it was found that the beverage of the present invention had significantly better skin moisturizing and elasticity improving effects than the beverage of the comparative example.
Claims (4)
A collagen peptide and a Guji extract, wherein the collagen peptide has improved blood transitivity.
2. The collagen peptide blood transitivity improving beverage composition of claim 1, wherein the extract of Gujuga extract is a Gujuga fermentation extract.
3. The collagen peptide blood transitivity improving beverage composition according to claim 1 or 2, wherein the extraction solvent of the extract is water or ethanol.
The beverage composition according to any one of claims 1 to 3, wherein the extract is from 0.5 to 50 parts by weight per 100 parts by weight of the collagen peptide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160135485A KR101895413B1 (en) | 2016-10-19 | 2016-10-19 | Beverage composition having an outstanding absorptive property of collagen peptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160135485A KR101895413B1 (en) | 2016-10-19 | 2016-10-19 | Beverage composition having an outstanding absorptive property of collagen peptide |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180042916A true KR20180042916A (en) | 2018-04-27 |
KR101895413B1 KR101895413B1 (en) | 2018-09-06 |
Family
ID=62081401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160135485A KR101895413B1 (en) | 2016-10-19 | 2016-10-19 | Beverage composition having an outstanding absorptive property of collagen peptide |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101895413B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101382758B1 (en) * | 2009-04-28 | 2014-04-08 | 가부시키가이샤 메이지 | Collagen peptide composition having good blood transfer properties, and food and drink containing same |
KR20160022512A (en) * | 2014-08-20 | 2016-03-02 | 김구환 | Chicken feet, dandelion, per ear and are made to go week herbal collagen beauty enhancement food manufacturing method |
-
2016
- 2016-10-19 KR KR1020160135485A patent/KR101895413B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101382758B1 (en) * | 2009-04-28 | 2014-04-08 | 가부시키가이샤 메이지 | Collagen peptide composition having good blood transfer properties, and food and drink containing same |
KR20160022512A (en) * | 2014-08-20 | 2016-03-02 | 김구환 | Chicken feet, dandelion, per ear and are made to go week herbal collagen beauty enhancement food manufacturing method |
Non-Patent Citations (2)
Title |
---|
1: [일본 수의학회 학술 집회 강연 요지집, Vol.132nd, Page 126, PS-5014(2001.09.07)] |
김미향. 갱년기 장애 유도 시 구기자의 혈중지질 농도 저하 및 골 중 collagen 합성 효과. 동의생리병리학회지 제21권 제1호. pp.111~116. (2007.02.).* * |
Also Published As
Publication number | Publication date |
---|---|
KR101895413B1 (en) | 2018-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101277713B (en) | Composition for acceleration of type I collagen production | |
TWI381834B (en) | Abnormal protein removal composition | |
US9198945B2 (en) | Cosmetic compositoin containing a rubus coreanus extract for diminishing skin wrinkles | |
KR20050114677A (en) | Composition for promoting production of type i collagen and/or elastin | |
CN108348565A (en) | A kind of composition for preventing and treating muscle disease or improving muscle function containing Radix Platycodonis extract | |
TW201302242A (en) | Collagen production promoter, hyaluronic acid production promoter, fibroblast proliferation promoter and anti-wrinkle agent | |
CN105769725A (en) | Rosemary moisturizing water and making method thereof | |
JP2016160198A (en) | Kaempferia parviflora-containing compositions | |
CN110693025B (en) | Composition with synergistic effect of multifunctional components for reducing blood sugar and application thereof | |
JP6765090B2 (en) | Black ginger-containing composition | |
KR101895413B1 (en) | Beverage composition having an outstanding absorptive property of collagen peptide | |
WO2022169066A1 (en) | Functional collagen composition using aurea helianthus-derived collagen amino acid | |
KR100329365B1 (en) | Antlers of the deer fermented with chicken gizzard lining and their method of preparation | |
KR20100008541A (en) | Composition for promoting the differentiation of human mesenchymal stem cell to adipocytic cells containing the extracts of trichosanthis semen or cannabis semen | |
CN113616573A (en) | I type collagen production promoter | |
EP3756647A1 (en) | Composition containing skunk cabbage extract or fraction thereof as active ingredient for wrinkle relief | |
CA3120845A1 (en) | Agent for inhibiting reduction in decomposition of denatured elastin, agent for maintaining normal elastin fibers, agent for inhibiting formation of elastin-elafine composite, and screening method for substance having elastin-elafine composite formation inhibitory effect | |
KR102677730B1 (en) | Peptide for lipolysis and their uses | |
CN107625135A (en) | A kind of health food for adjusting female incretion | |
KR101114006B1 (en) | Composition for cosmetic or plastic surgery containing the extracts of Hedyotidis Diffusae Herba | |
CN106975068A (en) | A kind of pigskin collagen small peptide active component composition | |
CN108355126A (en) | A kind of composite soybean protein maize oligopeptide capsule and preparation method thereof | |
CN107811299A (en) | A kind of female health food and preparation method thereof | |
JP7513299B2 (en) | Oral composition for inhibiting elastase and use thereof, elastase inhibitor, and method for inhibiting elastase activity by orally taking an elastase inhibitor | |
JP2021191794A (en) | Kaempferia parviflora-containing compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |